Natera Past Earnings Performance

Past criteria checks 0/6

Natera's earnings have been declining at an average annual rate of -17.3%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been growing at an average rate of 31.6% per year.

Key information

-17.3%

Earnings growth rate

-9.6%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate31.6%
Return on equity-24.4%
Net Margin-14.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Subdued Growth No Barrier To Natera, Inc. (NASDAQ:NTRA) With Shares Advancing 25%

Nov 19
Subdued Growth No Barrier To Natera, Inc. (NASDAQ:NTRA) With Shares Advancing 25%

Natera, Inc. (NASDAQ:NTRA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$158

Nov 15
Natera, Inc. (NASDAQ:NTRA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$158

Natera And GeneDx: Outperforming Market Powered By Precision Medicines Tailwinds

Oct 31

Natera, Inc.'s (NASDAQ:NTRA) Intrinsic Value Is Potentially 20% Below Its Share Price

Sep 18
Natera, Inc.'s (NASDAQ:NTRA) Intrinsic Value Is Potentially 20% Below Its Share Price

Does Natera (NASDAQ:NTRA) Have A Healthy Balance Sheet?

Jul 05
Does Natera (NASDAQ:NTRA) Have A Healthy Balance Sheet?

Natera: Overdue For A Breather

Jun 03

Natera, Inc. (NASDAQ:NTRA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$119

May 12
Natera, Inc. (NASDAQ:NTRA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$119

Is There An Opportunity With Natera, Inc.'s (NASDAQ:NTRA) 41% Undervaluation?

Mar 30
Is There An Opportunity With Natera, Inc.'s (NASDAQ:NTRA) 41% Undervaluation?

Natera: Capitalizing On The Positive Momentum Of Personalized Medicine

Mar 22

Is Natera (NASDAQ:NTRA) A Risky Investment?

Mar 03
Is Natera (NASDAQ:NTRA) A Risky Investment?

Revenue & Expenses Breakdown

How Natera makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:NTRA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,532-215768358
30 Jun 241,361-292708338
31 Mar 241,209-365663327
31 Dec 231,083-435618321
30 Sep 23989-499601326
30 Jun 23931-512594314
31 Mar 23868-546591318
31 Dec 22820-548589316
30 Sep 22776-546592300
30 Jun 22723-576572333
31 Mar 22667-546550304
31 Dec 21625-472511264
30 Sep 21565-408453231
30 Jun 21505-315402157
31 Mar 21449-258346122
31 Dec 20391-230304100
30 Sep 20362-18927277
30 Jun 20342-15325165
31 Mar 20330-12622658
31 Dec 19302-12520451
30 Sep 19286-12118949
30 Jun 19273-12817049
31 Mar 19262-12916148
31 Dec 18258-12815551
30 Sep 18243-14416350
30 Jun 18233-14215950
31 Mar 18223-13715650
31 Dec 17210-13815550
30 Sep 17207-12814449
30 Jun 17205-12614447
31 Mar 17205-12114346
31 Dec 16213-10013642
30 Sep 16221-8112938
30 Jun 16212-7212234
31 Mar 16205-6911731
31 Dec 15190-7011028
30 Sep 15187-469824
30 Jun 15189-288621
31 Mar 15179-67219
31 Dec 14159-56317
30 Sep 14133-115516
31 Mar 1478-294013
31 Dec 1355-373212

Quality Earnings: NTRA is currently unprofitable.

Growing Profit Margin: NTRA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NTRA is unprofitable, and losses have increased over the past 5 years at a rate of 17.3% per year.

Accelerating Growth: Unable to compare NTRA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NTRA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: NTRA has a negative Return on Equity (-24.44%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 21:44
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Natera, Inc. is covered by 27 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Catherine Ramsey SchulteBaird
Raymond MyersBenchmark Company
Navann Ty DietschiBNP Paribas Exane